Dash Bio Secures $30 Million in Series A Funding Led by Oak HC/FT
Dash Bio, a company specializing in an advanced platform for high-quality, accelerated bioanalysis, has successfully raised $30 million in a Series A funding round. The financing was led by Oak HC/FT, with participation from Freestyle Capital and Swift Ventures.
Company Background
Dash Bio offers a modern, automated platform designed to streamline the bioanalysis process for pharmaceutical and biotechnology companies. This platform integrates robotics, a proprietary laboratory operating system, and standardized assay workflows to significantly speed up the testing process. As a result, Dash Bio can deliver preclinical sample results in days rather than months, a stark contrast to traditional methods.
Founders and Leadership
The company was co-founded by CEO Dave Johnson and COO Ander Tallett. Johnson commented on the motivation behind the company's inception: "Sponsors and patients can’t wait. We built Dash on a deep conviction: the pace of drug development should be set by the science, not by queues and legacy process."
Use of Funds
The newly acquired funds will be directed towards expanding Dash Bio's commercial operations and laboratory capacity. The company also plans to broaden its assay menu and enter additional testing categories. Furthermore, Dash Bio intends to continue developing its proprietary software platform to enhance its service offerings.
Market Context and Growth
The bioanalysis market, valued at approximately $5 billion, largely relies on manual labor and paper records, resulting in extended turnaround times. Dash Bio's automated platform addresses these inefficiencies, offering fixed, transparent pricing and end-to-end digital traceability. Since launching its commercial operations around nine months ago, Dash Bio has secured contracts with over 30 customers, including four of the world's 15 largest pharmaceutical companies. Customers have noted the company's rapid turnaround times and pricing transparency as key differentiators.
With this significant investment, Dash Bio is poised to further advance its mission of modernizing the bioanalysis sector, making it more efficient and accessible for pharmaceutical developers worldwide.